3B BlackBio DX (formerly Kilpest India Limited) has reported strong financial results for the quarter ended September 30, 2025, with significant revenue growth and a major acquisition.

Financial Highlights

All figures in lakhs of rupees, except percentages

Revenue Growth

3B BlackBio DX reported a standalone revenue of 2,791.60 lakhs for the quarter, marking a significant increase of 37.1% compared to 2,035.70 lakhs in the previous quarter. This substantial growth in revenue indicates the company's strong market performance and increased sales.

Profitability

The company's standalone net profit showed impressive growth, increasing to 1,494.08 lakhs from 1,246.04 lakhs in the previous quarter. This represents a quarter-over-quarter growth of 19.9%.

Consolidated Performance

On a consolidated basis, 3B BlackBio DX reported a revenue of 3,890.21 lakhs for the quarter. This figure includes the performance of its newly acquired subsidiary, Coris Holding SRL, Belgium, from the acquisition date of August 29, 2025.

Business Segments

The company operates in two primary business segments:

1. Agrochemicals
2. Molecular Diagnostic Kits

Earnings Per Share

The basic earnings per share on a standalone basis was Rs 17.44 for the quarter, reflecting the company's strong profitability.

Strategic Acquisition

3B BlackBio DX completed the acquisition of Coris Holding SRL, Belgium on August 29, 2025. This strategic move is expected to enhance the company's product portfolio and international presence. The financial results of Coris Holding have been included in the consolidated figures from the acquisition date.

One-time Expenses

The company incurred one-time expenses of Rs 54.54 lakhs related to M&A advisory and due diligence for the Coris acquisition. These expenses reflect the company's investment in strategic growth through acquisitions.

Market Position

With its strong financial performance and recent acquisition, 3B BlackBio DX appears well-positioned in the molecular diagnostics and agrochemicals sectors. The significant revenue growth and strategic expansion demonstrate the company's current market strength.

3B BlackBio Dx Limited , a leading player in India's molecular diagnostics market, has reported strong financial results for the first quarter of fiscal year 2026, along with a strategic international acquisition.

Q1 FY26 Financial Highlights

The company reported sales of ₹19.96 crores for Q1 FY26, representing an impressive 18% year-on-year increase from ₹16.94 crores in the same quarter last year. EBITDA grew by 11% to reach ₹16.19 crores.

Strategic Acquisition

In a significant move to expand its global footprint, 3B BlackBio Dx has acquired Coris Bioconcept, a Belgium-based rapid diagnostics company, for up to £4.77 million. This acquisition is expected to strengthen the company's presence in the European market and broaden its product portfolio.

Market Position and Growth Outlook

3B BlackBio Dx currently holds a 12-15% market share in India's molecular diagnostics market. The company is projecting a growth rate of 15-20% for FY26, outpacing the industry's expected growth of 8-10%.

Business Segment Performance

The company aims to increase its export contribution from the current 17-18% to 35-40% of total revenue within the next five years.

Profitability and Capacity Utilization

EBITDA margins for the core business are approximately 60%, although the company expects these to trend towards 55% due to increasing competition. Current capacity utilization stands at 65%, with no major capital expenditure required for the next 2-3 years.

Future Outlook

With its strong market position, strategic acquisition, and focus on both domestic and export growth, 3B BlackBio Dx is well-positioned to capitalize on the expanding molecular diagnostics market. The company's emphasis on research and development, coupled with its efficient capital utilization, suggests a promising outlook for sustained growth and profitability.

Investors and industry observers will be keen to watch how the integration of Coris Bioconcept progresses and how it contributes to 3B BlackBio Dx's international expansion strategy in the coming quarters.